← All compounds
FDA ApprovedFDA Approved

PT-141

Melanocortin Receptor Agonist | Sexual Dysfunction Treatment

PT-141 (Bremelanotide) is an FDA-approved synthetic peptide that acts as a melanocortin receptor agonist, specifically targeting MC3R and MC4R receptors in the central nervous system. Unlike traditional ED medications that work through vascular mechanisms, PT-141 directly influences sexual arousal pathways in the brain, making it effective for both male and female sexual dysfunction.

Daily dose

1.75mg

Frequency

As needed

Cycle length

No cycling required

Storage

2-8°C

Key benefits

FDA-approved route with predictable absorption, works within 45 minutes, effective for both male and female sexual dysfunction

How it works

Activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of vascular mechanisms

Dosage protocols

Goal

Female HSDD (FDA-approved)

Dose

1.75mg · As needed, max 1 dose/24hr

Route

Subcutaneous (abdomen/thigh)

Goal

Male Erectile Dysfunction

Dose

1-2mg · As needed, 45-60min before activity

Route

Subcutaneous

Goal

Female Arousal Disorder

Dose

0.75-1.25mg · As needed, max 1 dose/24hr

Route

Subcutaneous

Goal

Low Starting Dose

Dose

0.5mg · Test dose to assess tolerance

Route

Subcutaneous

Research indications

hormonal

Hypoactive Sexual Desire Disorder (HSDD) — FDA-approved for premenopausal women with acquired, generalized HSDD
Erectile Dysfunction — Effective in men including those unresponsive to PDE5 inhibitors
Female Sexual Arousal Disorder — Improves physiological and subjective arousal measures

mood

Reduced Sexual Distress — Clinical trials show significant reduction in distress related to low sexual desire
Enhanced Sexual Satisfaction — Improvements in overall sexual satisfaction scores in both partners
Psychological Well-being — Positive effects on relationship satisfaction and quality of life

metabolic

Metabolic Neutral — No significant effects on glucose metabolism unlike some melanocortin agonists
Weight Neutral — Unlike Melanotan II, minimal effects on appetite or weight
Cardiovascular Safety — Extensive safety data shows manageable cardiovascular profile

Administration

injectable
nasal

Interactions

Monitor Combination
Sildenafil/Tadalafil — Can be used together but monitor for additive blood pressure effects. PT-141 works centrally while PDE5 inhibitors work peripherally.
Use Caution
Melanotan II — Both are melanocortin agonists - combining may lead to excessive melanocortin activation and side effects. Not recommended without medical supervision.
Monitor Combination
Blood Pressure Medications — PT-141 can transiently lower blood pressure. Monitor BP closely when combining with antihypertensives.
Use Caution
Alcohol — Both can lower blood pressure and cause flushing. Limit alcohol intake when using PT-141 to avoid excessive hypotension.
Avoid Combination
Nitrates — Risk of severe hypotension. Do not use PT-141 with nitrate medications for heart conditions.
Compatible
BPC-157 — No known interactions. Different mechanisms of action - PT-141 for sexual function, BPC-157 for tissue repair.
Synergistic
Testosterone — May work synergistically for sexual dysfunction. PT-141 addresses arousal while testosterone supports libido and function.
Monitor Combination
Kisspeptin — Both affect sexual function through different pathways - PT-141 via melanocortin receptors (MC3R/MC4R), Kisspeptin via GnRH stimulation. No receptor overlap but monitor for additive effects on blood pressure and hormonal response.

Safety notes

Common side effects: nausea (40%), flushing (20%), headache (11%)

Take anti-nausea medication 30 minutes before if prone to nausea

Monitor blood pressure - can cause transient decrease

Not for use with uncontrolled hypertension or cardiovascular disease

Avoid alcohol to minimize blood pressure effects

FDA black box warning for blood pressure effects

Research studies

FDA Approval Trial for Hypoactive Sexual Desire Disorder (2019)

Human | 1.75mg subcutaneous | As needed | 24.5% improvement vs 17.2% placebo

Phase 3 trials in premenopausal women with HSDD showed statistically significant improvements in sexual desire and reduced distress related to low sexual desire.

Male Erectile Dysfunction Clinical Trial (2017)

Human | 1-20mg intranasal | Single dose | Dose-dependent erectile response

Clinical studies demonstrated PT-141 induced erections in men with ED, including those unresponsive to PDE5 inhibitors, through central nervous system pathways.

Mechanism of Action Study (2016)

In vitro + Animal | Various doses | Receptor binding assays

Research confirmed PT-141 selectively binds MC3R and MC4R receptors, activating neural pathways involved in sexual arousal without peripheral vasodilation.

Female Sexual Arousal Disorder Trial (2013)

Human | 0.75-1.25mg subcutaneous | Single dose | Improved arousal metrics

Placebo-controlled study showed improvements in vaginal blood flow and subjective arousal measures in postmenopausal women with arousal disorder.

Related compounds

Melanotan IIKisspeptinOxytocinMelanotan I